Earlier this month, the Federal Circuit vacated an injunction in the Amgen v. Sanofi litigation that would have otherwise prohibited the sale of Sanofi and Regeneron’s Praluent® (alirocumab) product in the United States until expiration of the patents-in-suit. Today, Amgen filed a motion to extend the time for it to file…